Compare GNS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNS | ACET |
|---|---|---|
| Founded | 2002 | 1947 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 28.0M |
| IPO Year | 2021 | 2017 |
| Metric | GNS | ACET |
|---|---|---|
| Price | $0.49 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $29.00 |
| AVG Volume (30 Days) | ★ 2.5M | 284.0K |
| Earning Date | 09-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 197.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $127.02 | N/A |
| Revenue Next Year | $36.19 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.46 |
| 52 Week High | $0.83 | $9.97 |
| Indicator | GNS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 90.23 | 13.48 |
| Support Level | $0.36 | N/A |
| Resistance Level | N/A | $9.51 |
| Average True Range (ATR) | 0.03 | 0.26 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 59.66 | 0.84 |
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).